RxDoctor Payments Data

Kimberly Norris, MD

Ophthalmology · Hastings, MINPI 1659335305

Payments from drug & device makers

$3,239in general payments, 2019–2025

Across 148 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$623
  • Alcon$348
  • AbbVie$309
  • Sun Pharmaceutical Industries Inc.$268
  • Tarsus Pharmaceuticals, Inc.$200
  • Kala Pharmaceuticals, Inc.$191
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,17098%
  • Entertainment$692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,239 in reported general payments places this provider in the 75th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$129,617
Medicare patients
581
Services billed
1,432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine323$274,093
XdemvyLotilaner94$175,837
Cyclosporine106$37,705
LumiganBimatoprost81$32,341
RocklatanNetarsudil Mesylat/Latanoprost73$27,788
Restasis MultidoseCyclosporine12$16,743
RhopressaNetarsudil Mesylate29$11,488
SimbrinzaBrinzolamide/Brimonidine Tart30$8,971
Latanoprost521$8,016
VyzultaLatanoprostene Bunod18$7,809
Alphagan PBrimonidine Tartrate17$5,778
Travoprost27$5,152
Fluorometholone62$4,788
CombiganBrimonidine Tartrate/Timolol17$4,671
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat143$4,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose, Alphagan P, Combigan$309$333,626450 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$200$175,83794 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$37$39,276102 claims
AlconSimbrinza$348$8,97130 claims
Bausch & Lomb Americas Inc.Vyzulta$138$7,80918 claims
NovartisTravatan Z$124$3,93017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Hastings

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →